85 related articles for article (PubMed ID: 30293232)
1. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens.
Blancas I; Aguirre E; Morales S; Gonzálvez ML; Servitja S; Díaz N; Del Barco S; Barnadas A; Margelí M; García Carbonero I; Llombart A
Clin Transl Oncol; 2019 Apr; 21(4):459-466. PubMed ID: 30293232
[TBL] [Abstract][Full Text] [Related]
2. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
Macpherson IR; Spiliopoulou P; Rafii S; Saggese M; Baird RD; Garcia-Corbacho J; Italiano A; Bonneterre J; Campone M; Cresti N; Posner J; Takeda Y; Arimura A; Spicer J
Breast Cancer Res; 2019 Dec; 22(1):1. PubMed ID: 31892325
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Ahn JH; Kim SB; Kim TW; Ahn SH; Kim SM; Park JM; Lee JS; Kang YK; Kim WK
J Korean Med Sci; 2004 Aug; 19(4):547-53. PubMed ID: 15308846
[TBL] [Abstract][Full Text] [Related]
5. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
[TBL] [Abstract][Full Text] [Related]
7. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
8. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Al-Batran SE; Güntner M; Pauligk C; Scholz M; Chen R; Beiss B; Stopatschinskaja S; Lerbs W; Harbeck N; Jäger E
Br J Cancer; 2010 Nov; 103(10):1518-23. PubMed ID: 20978502
[TBL] [Abstract][Full Text] [Related]
10. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.
Sideras K; Dueck AC; Hobday TJ; Rowland KM; Allred JB; Northfelt DW; Lingle WL; Behrens RJ; Fitch TR; Nikcevich DA; Perez EA
Clin Breast Cancer; 2012 Dec; 12(6):387-91. PubMed ID: 23083501
[TBL] [Abstract][Full Text] [Related]
11. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.
Jin N; Xu Y; Wang S; Sun C; Yan X; Yang F; Liang Y; Chen W; Huang X
Cancer Pathog Ther; 2024 Jan; 2(1):31-37. PubMed ID: 38328709
[TBL] [Abstract][Full Text] [Related]
12. Third-line pyrotinib, trastuzumab (Zercepac®) and vinorelbine for brain metastases of HER2-positive advanced breast cancer patient.
Wang H; Shao B; DI L
Minerva Med; 2024 Apr; 115(2):257-259. PubMed ID: 35785951
[No Abstract] [Full Text] [Related]
13. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.
Gampenrieder SP; Bartsch R; Matzneller P; Pluschnig U; Dubsky P; Gnant MX; Zielinski CC; Steger GG
Breast Care (Basel); 2010; 5(3):158-162. PubMed ID: 21048830
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
Zhu A; Yuan P; Hu N; Li M; Wang W; Wang X; Yue J; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B; Cao S; Lippi G; Naito Y; Osman MA; Marta GN; Franceschini G; Orlandi A
Cancer Biol Med; 2021 May; 18(3):875-87. PubMed ID: 34037346
[TBL] [Abstract][Full Text] [Related]
15. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Halfter K; Hoffmann O; Ditsch N; Ahne M; Arnold F; Paepke S; Grab D; Bauerfeind I; Mayer B
J Transl Med; 2016 May; 14(1):112. PubMed ID: 27142386
[TBL] [Abstract][Full Text] [Related]
16. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
Shimomura A; Sagara Y; Koto R; Fujiwara M; Kanemura Y; Kitagawa H; Saji S
Breast Cancer; 2024 Apr; ():. PubMed ID: 38679657
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Munster P; Krop IE; LoRusso P; Ma C; Siegel BA; Shields AF; Molnár I; Wickham TJ; Reynolds J; Campbell K; Hendriks BS; Adiwijaya BS; Geretti E; Moyo V; Miller KD
Br J Cancer; 2018 Oct; 119(9):1086-1093. PubMed ID: 30361524
[TBL] [Abstract][Full Text] [Related]
19. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
Hurvitz SA; Quek RGW; Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke E; Mina LA; Balmaña J; Fasching PA; Bhattacharyya H; Hannah AL; Robson ME; Wardley AM
Eur J Cancer; 2018 Nov; 104():160-168. PubMed ID: 30359909
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Martin N; Isambert N; Gomez-Roca C; Goeldner RG; Zanetta S; Sadrolhefazi B; de Mont-Serrat H; Campone M; Delord JP
Cancer Chemother Pharmacol; 2018 Dec; 82(6):979-986. PubMed ID: 30350178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
